Announcement

Collapse
No announcement yet.

Eurosurv. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe

Collapse
X
  • Filter
  • Time
  • Show
Clear All
new posts

  • Eurosurv. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe

    E Kissling 1 2 , M Rondy 1 2 , I-MOVE/I-MOVE+ study team 3 + Author affiliations
    1. EpiConcept, Paris, France
    2. Both authors have contributed equally to the study and manuscript writing
    3. The members of I-MOVE/I-MOVE+ study team are listed at the end of the article


    Correspondence: Esther Kissling ()








    Citation style for this article: Kissling E, Rondy M, I-MOVE/I-MOVE+ study team. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Euro Surveill. 2017;22(7):pii=30464. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2017.22.7.30464

    Received:09 February 2017; Accepted:16 February 2017

    We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 014, 1564 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 6579 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).

    full article

    http://www.eurosurveillance.org/View...rticleId=22718



Working...
X